ReviewFrontiers in microbiology2025
The bioprospecting potential of insect venoms as antibiotics: a mini review.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise of antimicrobial resistance has intensified the search for new antibiotic candidates from unconventional biological sources. Insect venoms, although underexplored compared to other venomous taxa, harbor a chemically diverse array of antimicrobial peptides (AMPs) with significant therapeutic promises. This mini review synthesizes evidence from 15 original studies published over the past 15 years that examined the antimicrobial potential of insect venom components. Most investigations have focused on Hymenoptera-wasps, bees, and ants-where peptides such as mastoparans, polydim-I, macropin, melectin, and panurgines that exhibit broad-spectrum activity against multidrug-resistant bacteria while maintaining low toxicity toward mammalian cells. Collectively, these findings highlight insect venoms as a promising resource for antibiotic discovery. Nevertheless, critical challenges remain regarding peptide stability, delivery, pharmacokinetics, and clinical validation. Addressing these gaps through integrative approaches combining molecular, computational, and translational research will be key to advancing insect venom peptides as next-generation anti-infective agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.